Which Questionnaire Should Be Used to Measure Quality-of-Life Utilities in Patients with Acute Leukemia? An Evaluation of the Validity and Interpretability of the EQ-5D-5L and Preference-Based Questionnaires Derived from the EORTC QLQ-C30

Dongen‐Leunis, Annemieke van; Redekop, William K.; Groot, Carin A. Uyl–de

doi:10.1016/j.jval.2016.05.008

Cited by 19 publications

(15 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In their analysis of data from a large population-based cancer cohort, Lorgelly et al [9] found that the two instruments showed high correlation but poor agreement. As in our study, van Dongen-Leunis et al [31] found that PBM derived from the EORTC-QLQ30 and the EQ-5D-5L showed good convergent and known groups' validity in acute leukemia patients, though the disease-specific PBM showed greater discriminatory power than EQ-5D-5L. In multiple myeloma patients, Rowen et al [32] found that EORTC-8D utility estimates were broadly comparable to those obtained using EQ-5D, but that EORTC-8D better captured changes in HRQOL patients in mild health states.…”

Section: Discussionsupporting

confidence: 83%

“…Although this is the first study to compare the performance of EQ-5D-5L with the FACT-8D, other studies have compared the performance of EQ-5D with the EORTC-8D, a cancer-specific PBM scored from the EORTC QLQ-C30 questionnaire [9,31,32]. In their analysis of data from a large population-based cancer cohort, Lorgelly et al [9] found that the two instruments showed high correlation but poor agreement.…”

Section: Discussionmentioning

confidence: 94%

See 1 more Smart Citation

Testing the validity and responsiveness of a new cancer-specific health utility measure (FACT-8D) in relapsed/refractory mantle cell lymphoma, and comparison to EQ-5D-5L

Herdman

Kerr

Pavesi

et al. 2020

J Patient Rep Outcomes

View full text Add to dashboard Cite

Background: The FACT-8D is a new cancer-specific, preference-based measure (PBM) of health, derived from the Functional Assessment of Cancer Therapy-General (FACT-G) questionnaire. The FACT-8D's measurement properties have not been tested to date. We assessed it's validity and responsiveness in relapsed/refractory mantle cell lymphoma (RR MCL) and compared the results to the EQ-5D-5L. Methods: Blinded analysis of pooled data from a phase 3 clinical trial. FACT-8D baseline and follow-up data (weeks 4, 7, 16, 31) were scored using Australian preference weights, the first available value-set. Convergent validity was assessed by estimating baseline correlations with the FACT-Lym total score, Trial Outcome Index (TOI), FACT-Lym lymphoma-specific sub-scale (LymS), EQ-5D Visual Analog Scale (VAS), and haemoglobin (HgB). Relevant clinical variables were used to categorise patients to test known groups' validity and responsiveness was investigated using data from baseline (n = 250) and week 31 (n = 130). Results were compared with EQ-5D-5L, scored using the UK 3L crosswalk and the 5L England value-sets. Results: The FACT-8D showed good convergent validity and responsiveness; baseline Pearson correlation coefficients between FACT-8D Index scores and other PRO measures were moderate to very strong (range: 0.49 for the EQ-VAS to 0.79 for FACT TOI) and the size of the change in FACT-8D Index scores at week 31 differed significantly (p < 0.005) between patients categorised as improved, worsened or stable using the FACT-Lym total score, LymS, and HgB. However, when assessing known groups' validity, FACT-8D failed to discriminate between patients categorised by health status on four of the seven variables analysed. Overall, FACT-8D and EQ-5D-5L performed similarly, although EQ-5D-5L showed better known groups' validity.

show abstract

Section: Discussionsupporting

confidence: 83%

Section: Discussionmentioning

confidence: 94%

Testing the validity and responsiveness of a new cancer-specific health utility measure (FACT-8D) in relapsed/refractory mantle cell lymphoma, and comparison to EQ-5D-5L

Herdman

Kerr

Pavesi

et al. 2020

J Patient Rep Outcomes

View full text Add to dashboard Cite

show abstract

“…Disease-specific instruments like the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 (EORTC QLQ-C30), Medical Research Council/EORTC Quality of Life Questionnaire Leukemia Module (MRC/EORTC QLQ-LEU), Functional Assessment of Cancer Therapy-General (FACT-G) and the Functional Assessment of Cancer Therapy-Leukemia(FACT-Leu) are commonly used to measure the HRQoL of patients with leukemia [ 6 – 10 ]. While they are valid and reliable, they cannot be used to generate health utility value for leukemia patients because they are not preference-based instruments [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

“…Ever since, scoring algorithms of EQ-5D-5L based on the general public’s health preferences were developed in many countries such as China [ 18 ], the UK [ 19 ] and Germany [ 20 ]. While EQ-5D-5L has been applied to cancer patients [ 11 ], It is rarely used to measure health status and health utility of patients with leukemia.…”

Section: Introductionmentioning

confidence: 99%

Assessment of the health utility of patients with leukemia in China

Zeng

Sui

et al. 2021

Health Qual Life Outcomes

View full text Add to dashboard Cite

Objectives This study aimed to assess the health utility of leukemia patients in China using the EQ-5D-5L, compare it with the population norms, and identify the potential factors associated with health utility. Methods A hospital based cross-sectional survey was conducted in three tertiary hospitals from July 2015 to February 2016. A total of 186 patients with leukemia completed the EQ-5D-5L and their health utility scores were calculated using the Chinese value set. EQ-5D-5L utility and dimensions scores of leukemia patients were compared with China’s population norms using Kruskal–Wallis test and chi square test. Potential factors associated with health utility were identified using Tobit regression. Results The mean EQ-5D-5L utility scores of patients with leukemia, grouped by either gender or age, were significantly lower than those of the general population (p < 0.001). The same results were found for individual dimensions of EQ-5D-5L, where leukemia patients reported more health problems than the general population (p < 0.001). The utility score of leukemia patients was found to be significantly related to medical insurance, religious belief, comorbidities, social support and ECOG performance status. Conclusion This study indicated that leukemia patients have worse health status compared to the general population of China and that multiple factors affect the health utility of the patients. The utility scores reported in this study could be useful in future cost-utility analysis.

show abstract

“…Preference‐based HRQoL measures are actively used as well in clinical studies, for example, among persons with type 2 diabetes, chronic obstructive disease in the lungs, asthma, and cardiovascular diseases (van Hout et al., ). Most frequently used are the preference‐based measures of health from the Short Form‐36 (Brazier, Roberts, & Deverill, ); the European Quality of Life, 5‐domain survey (van Dongen‐Leunis, Uyl‐de, & Groot, ; Kind, ); and the Health Utilities Index Mark 2, 3 (HUI 2, 3) (Hays et al., ; Horsman, Furlong, Feeny, & Torrance, ). Previously conducted were studies confirming the lack of significant differences in evaluating HRQoL with these tools (Herschorn, Kaplan, Sun, & Ntanios, ).…”

Section: Introductionmentioning

confidence: 99%

Health-related quality of life's dependence on socio-economic status and demographic characteristics among men with benign prostatic hyperplasia

et al. 2017

View full text Add to dashboard Cite

This study investigated the effect of socio-economic status (SES) on health-related quality of life (HRQoL) among persons with benign prostatic hyperplasia (BPH). The data were collected by way of surveying persons with BPH aged from 35 to 85 (937) and selected via random sample. The diagnosis was confirmed with the use of I-PSS questionnaires (8-19 points), OABq-AT (≥8 points) and daily urinations. A study on HRQoL was conducted using the SF-36 questionnaire. SES was evaluated using the patients' ambulance cards (F112U) and tax inspection documents with their written permission. Verification of the viability of the differences in the HRQoL level of patients with different SES was conducted in each age cohort using ANOVA. The goal of the multifactor regressive analysis using least weighted squares was identified as featuring the strongest relationships between SES and HRQoL. In comparing the average regression squares with average error squares, selection of the entry variables was conducted. Among persons with a BPH, the strongest relationship was discovered between profession, level of education, place of residence and HRQoL. A weaker relationship was identified between income and HRQoL, and there was no relationship between marital status and HRQoL. HRQoL among persons with a different level of SES figures aged 65+ proved homogeneous. We can expect HRQoL improvement among persons with BPH while increasing informedness on the possibilities for treating and improving help for workers of industrial and rural production residing in rural areas.

show abstract

Which Questionnaire Should Be Used to Measure Quality-of-Life Utilities in Patients with Acute Leukemia? An Evaluation of the Validity and Interpretability of the EQ-5D-5L and Preference-Based Questionnaires Derived from the EORTC QLQ-C30

Cited by 19 publications

References 42 publications

Testing the validity and responsiveness of a new cancer-specific health utility measure (FACT-8D) in relapsed/refractory mantle cell lymphoma, and comparison to EQ-5D-5L

Testing the validity and responsiveness of a new cancer-specific health utility measure (FACT-8D) in relapsed/refractory mantle cell lymphoma, and comparison to EQ-5D-5L

Assessment of the health utility of patients with leukemia in China

Health-related quality of life's dependence on socio-economic status and demographic characteristics among men with benign prostatic hyperplasia

Contact Info

Product

Resources

About